Full Length Research Paper
References
|
Abbas N, Kabil S (2017). Pentoxifylline and Cilostazol Against Rat Heart Injuries Induced by Doxorubicin. Egyptian Journal of Basic and Clinical Pharmacology 7 p. |
|
|
Badore NS, Das PK, Pillai S, Thakur A (2017). Role of Ginkgo biloba Extract, Against Isoproterenol Induced Cardiac Toxicity in Rats. Indian Journal of Pharmaceutical Education and Research 51(4):691-699. |
|
|
Deng XY, Chen JJ, Li HY, Ma ZQ, Ma SP, Fu Q (2015). Cardioprotective effects of Timosaponin B II from Anemarrhenae asphodeloides Bge on Isoproterenol-induced myocardial infarction in rats. Chemico-Biological Interactions 240:22-28. |
|
|
Dhakad P, Kumar P, Kumar S, Sharma A, Mishra R, Dixit A (2017). Cardio Protective Action of Cilostazol, Milrinone and Their Combination over Isoproterenol Induced Myocardial Infarction in Wistar Rats. International Journal of Cardiovascular and Cerebrovascular Disease 5(1):8-14. |
|
|
Eom YW, Jung HY, Oh JE, Lee JW, Ahn MS, Youn YJ, Ahn SG, Kim JY, Lee SH, Yoon J, Yoo BS (2016). Isoproterenol Enhances Tumor Necrosis Factor-Related Apoptosis- Inducing Ligand-Induced Apoptosis in Human Embryonic Kidney Cells through Death Receptor 5 up-Regulation. Korean Circulation Journal 46(1):93-98. |
|
|
Filho HJL, Ferreira NL, DeSousa RB, deCarvalho ER, Lobo PLD, Filho JGL (2011). Experimental model of myocardial infarction induced by Isoproterenol in rats. Brazilian Journal of Cardiovascular Surgery 26(3):469-476. |
|
|
Gamssari F, Mahmood H, Ho JS, Villareal RP, Liu B, Rasekh A, Massumi A (2002). Rapid ventricular tachycardias associated with cilostazol use.Texas Heart Institute Journal 29(2):140. |
|
|
Hao G, Duan W, Sun J, Liu J, Peng L (2019). Effects of Febuxostat on serum cytokines IL 1, IL 4, IL 6, IL 8, TNF α and COX-2 Experimental and Therapeutic Medicine 17(1):812-816. |
|
|
Jain B, Chaudhari S, Khatal S (2018). Evaluation of xanthine oxidase inhibitor Febuxostat in myocardial fibrosis. International Journal of Research in Pharmacy and Pharmaceutical Sciences 3(6):11-15. |
|
|
Kangawa Y, Yoshida T, Abe H, Seto Y, Miyashita T, Nakamura M, Kihara T, Hayashi SM and Shibutani M.(2016). Anti-inflammatory effects of the selective phosphodiesterase 3 inhibitor, Cilostazol, and antioxidants, enzymatically-modified Isoquercitrin and a-lipoic acid, reduce dextran sulphate sodium-induced colorectal mucosal injury in mice. Experimental and Toxicologic Pathology 69(4):179-186. |
|
|
Parikh H (2015). Investigation of cardioprotectivc effects of Crataegus oxycantha and its molecular mechanism. Current Research - Cardiology 2:4. |
|
|
Siriporn C, Chattipakorn I, Savitree T, Jantira S, Nipon C (2014). Phosphodiesterase-3 inhibitor (Cilostazol) attenuates oxidative stress-induced mitochondrial dysfunction in the heart. Journal of Geriatric Cardiology 11(2):151. |
|
|
Tanno S, Yamamoto K, Kurata Y, Adachi M, Inoue Y, Otani N, Mishima M, Yamamoto Y, Kuwabara M, Ogino K, Miake J, Ninomiya H, Shirayoshi Y, Okada F, Yamamoto K, Hisatome I (2018). Protective Effects of Topiroxostat on an Ischemia-Reperfusion Model of Rat Hearts. Circulation Journal 82(4):1101-1111. |
|
|
Wang S, Li Y, Song X, Wang X, Zhao C, Chen A, Yang P (2015). Febuxostat pretreatment attenuates myocardial ischemia/reperfusion injury via mitochondrial apoptosis. Journal of Translational Medicine 13(1):209 |
|
|
William B, Kenneth G, Michael A, Jeffrey S, Philip B, Whelton A, Hunt B, Castillo M and Gunawardhana L (2018). Cardiovascular Safety of Febuxostat or Allopurinol in Patients with Gout. New England Journal of Medicine 378(13):1200-1210. |
|
Copyright © 2025 Author(s) retain the copyright of this article.
This article is published under the terms of the Creative Commons Attribution License 4.0
